The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with schizophrenia.

Flu season is rapidly approaching, and COVID has not gone away. As more and more people are getting sick this time of year, ...

Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and ...

This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...

Shares of Pfizer Inc. PFE inched 0.14% higher to $28.97 Thursday, on what proved to be an all-around positive trading session ...

The company said benefits no longer outweighed the risks, with data suggesting the drug might increase the risk of pain ...

The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of ...

Pfizer has made the decision to withdraw Oxbryta (voxelotor), a treatment for sickle cell disease, from all markets where it is approved. Additionally, all clinical trials evaluating voxelotor, as ...

The autumn wave of coronavirus is sweeping across Germany. Those affected mainly suffer from coughs, colds, sore throats and ...